Nautilus Deferred Long Term Liab from 2010 to 2024
NAUT Stock | USD 2.24 0.06 2.61% |
Deferred Long Term Liabilities | First Reported 2010-12-31 | Previous Quarter 190.8 K | Current Value 169.6 K | Quarterly Volatility 11.9 K |
Check Nautilus Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Nautilus Biotechnology's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.8 M, Interest Expense of 7 M or Selling General Administrative of 25.5 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 2.12. Nautilus financial statements analysis is a perfect complement when working with Nautilus Biotechnology Valuation or Volatility modules.
Nautilus | Deferred Long Term Liab |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Nautilus Stock Analysis
When running Nautilus Biotechnology's price analysis, check to measure Nautilus Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nautilus Biotechnology is operating at the current time. Most of Nautilus Biotechnology's value examination focuses on studying past and present price action to predict the probability of Nautilus Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nautilus Biotechnology's price. Additionally, you may evaluate how the addition of Nautilus Biotechnology to your portfolios can decrease your overall portfolio volatility.